argenx is trading at $781.00 (-15.88%) in pre-market after its October 8 announcement that it would discontinue its Phase 3 UNITY study, which an independent committee concluded was unlikely to meet its primary endpoint. - The company also reported positive Phase 2 results for FB102 in celiac disease, meeting the primary endpoint, and plans to advance it into Phase 3. - Broader markets were softer, but the provided index moves were smaller than argenx’s decline; no trading-volume data was available.